$CNC

Burdick Kenneth A sold $5.2M of CNC

Burdick Kenneth A sold 80,000 shares of CENTENE CORP (CNC) at $64.55 ($5.16M total) on 2026-06-10.

Original reporting
SEC EDGAR · Burdick Kenneth A
Published Jun 11, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CNC
Bearish
medium confidence
Mentioned
$CNC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNCBearishLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings; it may slightly affect sentiment but lacks fundamental triggers.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is stated, but the filing alone cannot distinguish discretionary selling from scheduled personal liquidity needs; traders should check for repeated insider activity around the same period.

Relevance 6/10Novelty 6/10Timing: New SEC Form 4 filed June 11; sale executed June 10

Background

The article is an SEC Form 4 insider transaction disclosure for Centene’s director Kenneth A. Burdick.

Company-level read

Ticker impact

$CNCBearishMedium confidence
Context

Centene director Kenneth A. Burdick sold 80,000 shares in an open-market transaction worth about $5.164M, per a new SEC Form 4 filing.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not indicate company-specific deterioration (no earnings, guidance, or regulatory action) and notes no 10b5-1 plan.

Market effects

Minimal; single-insider sale does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect forward-looking views, especially without evidence of a broader pattern.

Key entities

  • CENTENE CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • Burdick Kenneth A

    Director who sold 80,000 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNCMed

CNC Looks 14.6% Undervalued on GF Value™ as Market Prices in Gro

Centene Corporation (CNC) reaffirmed its 2026 adjusted diluted EPS forecast, expecting it to exceed $4.80, slightly below analyst consensus. The company's P/S ratio is 0.16, below its historical median and industry average, reflecting market skepticism. Its GF Score™ is 72/100, indicating moderate financial health. Insider activity shows no buying and $14.6 million in selling, while institutional sentiment is mixed.

$CNCMed

2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene Corp. (CNC) and Archer-Daniels-Midland Co. (ADM) are highlighted for strong performance and attractive valuations. CNC expects 2026 revenues of $173-$177B and adjusted EPS over $4.80, with a forward P/E of 13.58X. ADM raised 2026 adjusted earnings guidance to $5.15-$5.60 per share, with a forward P/E of 16.60X.

$CNCMed

CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.

$CNCMed

Centene (CNC) Hands Its Turnaround Playbook To A New Tech Chief

Centene Corporation (CNC) appointed Bradley Bolivar as its new Chief Information Officer, replacing Brian LeClaire. Bolivar brings extensive tech leadership experience, including roles at Fannie Mae and Warner Bros. Centene reported Q2 earnings of $2.19 GAAP EPS and $2.51 adjusted EPS, raising its full-year adjusted EPS guidance above $4.80. The company's health benefits ratio improved, but total at-risk membership declined. Centene trades at a forward P/E ratio of 13.12 as of September 1.

$CNCMed

Can Centene's Marketplace Recovery Fuel Stronger Earnings Growth?

Centene Corporation (CNC) reported improved profitability in its Marketplace business, with a health benefits ratio of 79.2% in Q2 2026, down from 90.6% a year ago. The company expects a 4.5%-5% pretax margin for 2026, up from a previous 3% outlook. Competitors UnitedHealth (UNH) and Elevance Health (ELV) are also focusing on profitability. CNC shares have surged 56.4% YTD, with a forward P/E of 12.39. Analysts estimate $4.89 EPS for 2026, a 135.1% increase.

$UNHHighAI 8/10

Health Insurer Stocks Are Soaring As Companies Get A Handle On Costs

UnitedHealth Group reported $5B in Q2 net income, with a declining medical care ratio. Shares of UnitedHealth, CVS Health, Centene, and Humana have risen significantly. Centene and Humana reported strong earnings, while Humana plans to exit some markets in 2027. Oscar Health entered new markets and saw its stock triple in six months.